LIQUID BASED
WHO
Diagnosed NSCLC patients
IDENTIFIES FOR
10 genes for multi-genetic biomarker
TURNAROUND TIME
6-10 working days
WHO
Lung cancer patients
SCREENS FOR
EGFR Exon 19 deletions, Exon 21 L858R, Exon 20 T790M, C797S mutations in plasma
TURNAROUND TIME
2-3 working days
WHO
Breast, ovarian, prostate cancer patients
SCREENS FOR
Mutated BRCA1 and BRCA2 - linked germline mutations
TURNAROUND TIME
Within 20 working days
WHO
Patients with advanced -solid tumours
IDENTIFIES FOR
74 genes with somatic mutations with reports on micro-satelitte instability status.
TURNAROUND TIME
Within 7 days of sample receipt in the US laboratory
+
3 days logistics
TISSUE BASED
WHO
NSCLC, gastric, endothelial and cervical cancer patients
DETECTS
Proportion of PD-L1 positive cell expression
TURNAROUND TIME
8 working days
WHO
Solid tumour patients
PROFILES FOR
466 genes for single nucleotide variations, insertions, deletions, selected fusions and copy number alternations
TURNAROUND TIME
14 working days
WHO
Breast, ovarian, prostate cancer patients
SCREENS FOR
Somatic mutations of BRCA1 and BRA2 genes
TURNAROUND TIME
14 working days
WHO
Primarily diagnosed NSCLC patients
SCREENS FOR
9 genes for multi-genetic biomarkers
TURNAROUND TIME
3-5 working days
PREIMPLANTATION GENETIC SCREENING
WHO
Females over 35, history of failed implantations, miscarriages or chromosomal abnormalities
SCREENS FOR
24 chromosomes of IVF and ICSI embryos to detect pathogenic chromosome copy number changes
TURNAROUND TIME
5-9 working days
